Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Short Interest Update

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) saw a significant decline in short interest in June. As of June 30th, there was short interest totaling 102,058 shares, a decline of 47.2% from the June 15th total of 193,285 shares. Approximately 2.4% of the company’s stock are sold short. Based on an average trading volume of 212,492 shares, the short-interest ratio is currently 0.5 days.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Cyclacel Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research report on Tuesday. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Cyclacel Pharmaceuticals currently has a consensus rating of “Sell”.

Cyclacel Pharmaceuticals Price Performance

Shares of NASDAQ BGMS traded down $0.06 during trading on Friday, hitting $0.89. The stock had a trading volume of 3,605 shares, compared to its average volume of 1,129,228. Cyclacel Pharmaceuticals has a 12 month low of $0.57 and a 12 month high of $19.87. The company has a market capitalization of $4.89 million, a PE ratio of -0.19 and a beta of -0.38. The firm has a fifty day moving average of $0.92 and a two-hundred day moving average of $1.04.

Cyclacel Pharmaceuticals (NASDAQ:BGMS) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.04) earnings per share for the quarter. The business had revenue of $0.78 million during the quarter.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.